Sydney – 24 April 2020 – Dupixent® (dupilumab), a first in class biologic therapy, has
been recommended for listing on the Pharmaceutical Benefits Scheme for the treatment of
eligible patients (12 years and above) with severe atopic dermatitis who have had an
inadequate response to topical corticosteroids and/or topical calcineurin inhibitors
Sanofi Genzyme Australia and New Zealand Head of Medical, Dr Paul King thanked the
PBAC for their recommendation and acknowledged the extensive feedback provided by
clinicians, patient support groups and individual patients who responded to the PBAC’s call
for consumer comments about Dupixent prior to the March meeting.
“We recognise the debilitating impact of severe atopic dermatitis on the lives of many
Australians and the incredibly challenging environment we are all addressing as a result of
“As a company we remain committed to supporting clinicians who have patients who are
receiving Dupixent through our early access scheme and look forward to working with the
Federal Government to support the earliest possible PBS listing for all eligible patients,” he
Dr King assured clinicians that the company will continue to provide Dupixent to patients
who are receiving the medicine through the company’s early access scheme, until the
medicine is added to the PBS. The scheme is no longer open for new patients.